These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial. Budau L; Wilhelm C; Moll R; Jäkel J; Hirt C; Dölken G; Maschmeyer G; Neubauer E; Strauch K; Burchert A; Herold M; Neubauer A J Cancer Res Clin Oncol; 2019 Aug; 145(8):2149-2156. PubMed ID: 31273513 [TBL] [Abstract][Full Text] [Related]
7. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434 [TBL] [Abstract][Full Text] [Related]
8. Immune infiltrate diversity confers a good prognosis in follicular lymphoma. Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583 [TBL] [Abstract][Full Text] [Related]
9. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724 [TBL] [Abstract][Full Text] [Related]
10. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760 [TBL] [Abstract][Full Text] [Related]
11. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404 [TBL] [Abstract][Full Text] [Related]
15. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915 [TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692 [TBL] [Abstract][Full Text] [Related]
18. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313 [TBL] [Abstract][Full Text] [Related]
19. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]